Recombinant IL-7: Additional Phase IIa data

Additional data from the open-label, North American Phase IIa INSPIRE 2 trial in 22 patients with chronic HIV-1 infection showed that weekly 20 µg/kg subcutaneous CYT107 for 3 weeks significantly incr...